Verdad Advisers’s Ovid Therapeutics OVID Stock Holding History

Verdad Advisers’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$337K	Buy	+151,919	New	+$272K	0.38%	91

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Verdad Advisers's OVID Position: Q1 2026 in Review

Verdad Advisers opened a new position in Ovid Therapeutics (OVID) in Q1 2026: 151,919 shares worth $337K. The stake represents 0.38% of the portfolio and ranks #91 among its holdings.

103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

Verdad Advisers held 151,919 shares of Ovid Therapeutics worth $337K as of Q1 2026.
Ovid Therapeutics was a new Verdad Advisers position in Q1 2026.
Ovid Therapeutics made up 0.38% of Verdad Advisers's portfolio in Q1 2026, its #91 holding.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.